Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,659 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pasireotide-induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment.
Shikata M, Ashida K, Goto Y, Nagayama A, Iwata S, Yano M, Hasuzawa N, Hara K, Mawatari K, Sakata K, Tsuruta M, Wada N, Nomura M. Shikata M, et al. Among authors: goto y. Clin Case Rep. 2020 Aug 13;8(12):2613-2618. doi: 10.1002/ccr3.3230. eCollection 2020 Dec. Clin Case Rep. 2020. PMID: 33363790 Free PMC article.
Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report.
Nagayama A, Ashida K, Moritaka K, Hidaka M, Gobaru M, Tanaka S, Hasuzawa N, Akasu S, Goto Y, Motomura S, Hara K, Tsuruta M, Wada N, Nakayama H, Tajiri Y, Nomura M. Nagayama A, et al. Among authors: goto y. J Endocr Soc. 2019 Sep 16;3(11):2179-2183. doi: 10.1210/js.2019-00251. eCollection 2019 Nov 1. J Endocr Soc. 2019. PMID: 31720553 Free PMC article.
Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes.
Sakamoto M, Goto Y, Nagayama A, Yano M, Sato S, Tajiri Y, Nomura M. Sakamoto M, et al. Among authors: goto y. Diabetol Int. 2021 May 21;13(1):117-123. doi: 10.1007/s13340-021-00512-7. eCollection 2022 Jan. Diabetol Int. 2021. PMID: 35059247 Free PMC article.
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K. Hata T, et al. Among authors: goto y. Clin Lung Cancer. 2025 Jan 4:S1525-7304(25)00001-4. doi: 10.1016/j.cllc.2025.01.002. Online ahead of print. Clin Lung Cancer. 2025. PMID: 39864962
Evaluation of optimal timing and therapeutic efficacy of radium-223 therapy for metastatic castration-resistant prostate cancer: a multicenter collaborative study.
Urabe F, Kadena S, Tashiro K, Tokuoka K, Taneda Y, Fujiwara K, Goto Y, Nakano J, Kawano S, Iwamoto Y, Fukuokaya W, Imai Y, Iwatani K, Atsuta M, Ito K, Yanagisawa T, Murakami M, Tsuzuki S, Yamamoto T, Shimomura T, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Urabe F, et al. Among authors: goto y. Jpn J Clin Oncol. 2025 Jan 17:hyaf007. doi: 10.1093/jjco/hyaf007. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39820640
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer.
Saw SPL, Zhong WZ, Fu R, Li MSC, Goto Y, Fox SB, Yatabe Y, Ong BH, Ng CSH, Lee DDW, Cam Phuong P, Park IK, Yang JCH, Tsuboi M, Tho LM, John T, Hsu HH, Tan DSW, Mok TSK, Reungwetwattana T, Singh N. Saw SPL, et al. Among authors: goto y. Lung Cancer. 2025 Jan 2;200:108076. doi: 10.1016/j.lungcan.2024.108076. Online ahead of print. Lung Cancer. 2025. PMID: 39799810 Free article. Review.
4,659 results